Article: Novuspharma SpA Announces Plans for Phase I Trial of Pixantrone (BBR 2778) in Multiple Sclerosis; Promising Results in Pre-Clinical Models Pave the Way For Preliminary Clinical Studies.

Article: Pixantrone to be Studied in Phase I/II Trial for ...
PR Newswire;  March 6, 2008 ;     700+ words ... ... in general and with pixantrone in particular including ... potential failure of pixantrone to prove safe and effective for treatment of multiple sclerosis, the identification ... risks or limitations of pixantrone that may be discovered ...

Article: Pixantrone Shows Activity in a Preclinical Study of ...
PR Newswire;  February 11, 2008 ;     700+ words ... ... study compared pixantrone with the related ... treat severe multiple sclerosis, also an autoimmune ... animal models of multiple sclerosis, suggest that pixantrone may be of clinical ... myasthenia gravis or multiple sclerosis. We have been ...

Article: Plans announced for phase I trial of pixantrone (BBR 2778) ...
Biotech Week;  January 8, 2003 ;     525 words ... ... begin a phase I trial of pixantrone (BBR 2778) in patients with multiple sclerosis (MS) in early 2003 ... to define the dose of pixantrone to be used in longer term ... receive 4 infusions of pixantrone every 3 weeks, with a ...

Article: Novuspharma to start trial of pixantrone in MS.
Pharma Marketletter;  December 9, 2002 ;     348 words ... ... will start in early 2003 a Phase I trial of pixantrone (BBR 2778) in multiple sclerosis. The drug is a DNA intercalator with an ... progressive MS who will receive four infusions of pixantrone, every three weeks, with a starting dose ...

Article: Pixantrone Combination Therapy for First-line Treatment of ...
PR Newswire;  July 11, 2007 ;     700+ words ... ... trial comparing CPOP-R, in which pixantrone is substituted for doxorubicin in standard ... results showed that patients who received pixantrone had a reduction in severe (grade 3 ... annual meeting in December. Despite pixantrone patients receiving more treatment cycles ...

Article: Pixantrone Granted Fast Track Designation by FDA for ...
PR Newswire;  May 7, 2007 ;     700+ words ... ... and Drug Administration (FDA) for pixantrone, a novel anthracenedione, being investigated ... Hodgkin's lymphoma suggest that pixantrone is active in this disease." The FDA ... results demonstrated that the addition of pixantrone to a fludarabine/rituximab-based ...

Article: Pixantrone Pre-NDA Communication from FDA Provides Cell ...
PR Newswire;  January 27, 2009 ;     700+ words ... ... NDA) and request priority review for pixantrone to treat relapsed aggressive non-Hodgkin ... a phase III single-agent trial of pixantrone for patients with relapsed, aggressive ... patients were randomized to receive either pixantrone or another single-agent drug currently ...